Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation

BEAT-AF and Swiss-AF investigators

doi:10.1016/j.hrthm.2020.11.028

Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation

BEAT-AF and Swiss-AF investigators

Clinical sciences

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

BACKGROUND: The occurrence of congestive heart failure (CHF) hospitalization among patients with atrial fibrillation (AF) is a poor prognostic marker.

OBJECTIVE: The purpose of this study was to assess whether insulin-like growth factor-binding protein 7 (IGFBP-7), a marker of myocardial damage, identifies AF patients at high risk for this complication.

METHODS: We analyzed 2 prospective multicenter observational cohort studies that included 3691 AF patients. Levels of IGFBP-7 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured from frozen plasma samples at baseline. The primary endpoint was hospitalization for CHF. Multivariable adjusted Cox regression analyses were constructed.

RESULTS: Mean patient age was 69 ± 12 years, 1028 (28%) were female, and 879 (24%) had a history of CHF. The incidence per 1000 patient-years across increasing IGFBP-7 quartiles was 7, 10, 32, and 85. The corresponding multivariable adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.0, 1.05 (0.63-1.77), 2.38 (1.50-3.79), and 4.37 (2.72-7.04) (P for trend <.001). In a subgroup of 2812 patients without pre-existing CHF at baseline, the corresponding aHRs were 1.0, 0.90 (0.47-1.72), 1.69 (0.94-3.04), and 3.48 (1.94-6.24) (P for trend <.001). Patients with IGFBP-7 and NT-proBNP levels above the biomarker-specific median had a higher risk of incident CHF hospitalization (aHR 5.20; 3.35-8.09) compared to those with only 1 elevated marker (elevated IGFBP-7 aHR 2.17; 1.30-3.60); elevated NT-proBNP aHR 1.97; 1.17-3.33); or no elevated marker (reference).

CONCLUSION: Higher plasma levels of IGFBP-7 were strongly and independently associated with CHF hospitalization in AF patients. The prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.

Original language	English
Pages (from-to)	512-519
Number of pages	8
Journal	Heart Rhythm
Volume	18
Issue number	4
DOIs	https://doi.org/10.1016/j.hrthm.2020.11.028
Publication status	Published - Apr 2021

Bibliographical note

Funding Information:
Funding sources: BEAT-AF was supported by the Swiss National Science Foundation (PP00P3_159322), Swiss Heart Foundation, University of Basel, Roche Diagnostics, Boehringer-Ingelheim, Sanofi-Aventis, Merck Sharp & Dohme, Bayer, Daiichi-Sankyo, Pfizer/Bristol Myers Squibb, and the Foundation for Cardiovascular Research Basel. Swiss-AF was supported by grants from the Swiss National Science Foundation (33CS30_1148474 and 33CS30_177520), Foundation for Cardiovascular Research Basel, University of Basel, and Roche Diagnostics. Plasma levels of NT-proBNP and IGFBP-7 were measured free of charge by Roche Diagnostics. Dr Blum is supported by the Mach-Gaensslen Foundation outside the submitted work. Dr Conen holds a McMaster University Department of Medicine Mid-Career Research Award. Disclosures: Dr K\u00FChne reports fees from Speakers Bureau for Boston Scientific, St. Jude Medical, and Biotronik; lecture/consulting fees from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis, Medtronic, and Pfizer-BMS; unrestricted grants from Bayer and Pfizer-Bristol Myers Squibb; and serving as a proctor for Medtronic (Cryoballoon). Dr Rodondi reports a grant from the Swiss Heart Foundation. Dr Beer reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and Bayer; lecture fees from Sanofi Aventis and Amgen; and support to the institution outside the submitted work. Dr Bonati reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation (Bern, Switzerland), and the University of Basel, Switzerland; unrestricted research grant from AstraZeneca; consultancy or advisory board fees or speaker honoraria from Amgen, Bayer, Bristol Myers Squibb, and Claret Medical; and travel grants from AstraZeneca and Bayer. Dr Kastner is an employee of Roche Diagnostics. Dr Sticherling reports speaker honoraria from Biosense Webster, Boston Scientific, and Medtronic; research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic; and serving as proctor for Medtronic (Cryoballoon). Dr Conen reports consultant/speaker fees from Servier Canada outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2020 Heart Rhythm Society

Keywords

Aged
Atrial Fibrillation/blood
Biomarkers/blood
Disease Progression
Female
Follow-Up Studies
Heart Failure/blood
Hospitalization/statistics & numerical data
Humans
Insulin-Like Growth Factor Binding Proteins/blood
Male
Middle Aged
Prognosis
Retrospective Studies

Access to Document

10.1016/j.hrthm.2020.11.028

Handle.net

Persistent link

Cite this

@article{e8782bd3324a4391aaab653c8090485d,

title = "Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation",

abstract = "BACKGROUND: The occurrence of congestive heart failure (CHF) hospitalization among patients with atrial fibrillation (AF) is a poor prognostic marker.OBJECTIVE: The purpose of this study was to assess whether insulin-like growth factor-binding protein 7 (IGFBP-7), a marker of myocardial damage, identifies AF patients at high risk for this complication.METHODS: We analyzed 2 prospective multicenter observational cohort studies that included 3691 AF patients. Levels of IGFBP-7 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured from frozen plasma samples at baseline. The primary endpoint was hospitalization for CHF. Multivariable adjusted Cox regression analyses were constructed.RESULTS: Mean patient age was 69 ± 12 years, 1028 (28%) were female, and 879 (24%) had a history of CHF. The incidence per 1000 patient-years across increasing IGFBP-7 quartiles was 7, 10, 32, and 85. The corresponding multivariable adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.0, 1.05 (0.63-1.77), 2.38 (1.50-3.79), and 4.37 (2.72-7.04) (P for trend <.001). In a subgroup of 2812 patients without pre-existing CHF at baseline, the corresponding aHRs were 1.0, 0.90 (0.47-1.72), 1.69 (0.94-3.04), and 3.48 (1.94-6.24) (P for trend <.001). Patients with IGFBP-7 and NT-proBNP levels above the biomarker-specific median had a higher risk of incident CHF hospitalization (aHR 5.20; 3.35-8.09) compared to those with only 1 elevated marker (elevated IGFBP-7 aHR 2.17; 1.30-3.60); elevated NT-proBNP aHR 1.97; 1.17-3.33); or no elevated marker (reference).CONCLUSION: Higher plasma levels of IGFBP-7 were strongly and independently associated with CHF hospitalization in AF patients. The prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.",

keywords = "Aged, Atrial Fibrillation/blood, Biomarkers/blood, Disease Progression, Female, Follow-Up Studies, Heart Failure/blood, Hospitalization/statistics & numerical data, Humans, Insulin-Like Growth Factor Binding Proteins/blood, Male, Middle Aged, Prognosis, Retrospective Studies",

author = "{BEAT-AF and Swiss-AF investigators} and Steffen Blum and Stefanie Aeschbacher and Pascal Meyre and Michael K{\"u}hne and Nicolas Rodondi and Beer, {J{\"u}rg H} and Peter Ammann and Giorgio Moschovitis and Bonati, {Leo H} and Blum, {Manuel R} and Peter Kastner and Fiona Baguley and Christian Sticherling and Stefan Osswald and David Conen and Giulio Conte",

note = "Funding Information: Funding sources: BEAT-AF was supported by the Swiss National Science Foundation (PP00P3_159322), Swiss Heart Foundation, University of Basel, Roche Diagnostics, Boehringer-Ingelheim, Sanofi-Aventis, Merck Sharp & Dohme, Bayer, Daiichi-Sankyo, Pfizer/Bristol Myers Squibb, and the Foundation for Cardiovascular Research Basel. Swiss-AF was supported by grants from the Swiss National Science Foundation (33CS30_1148474 and 33CS30_177520), Foundation for Cardiovascular Research Basel, University of Basel, and Roche Diagnostics. Plasma levels of NT-proBNP and IGFBP-7 were measured free of charge by Roche Diagnostics. Dr Blum is supported by the Mach-Gaensslen Foundation outside the submitted work. Dr Conen holds a McMaster University Department of Medicine Mid-Career Research Award. Disclosures: Dr K\u00FChne reports fees from Speakers Bureau for Boston Scientific, St. Jude Medical, and Biotronik; lecture/consulting fees from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis, Medtronic, and Pfizer-BMS; unrestricted grants from Bayer and Pfizer-Bristol Myers Squibb; and serving as a proctor for Medtronic (Cryoballoon). Dr Rodondi reports a grant from the Swiss Heart Foundation. Dr Beer reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and Bayer; lecture fees from Sanofi Aventis and Amgen; and support to the institution outside the submitted work. Dr Bonati reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation (Bern, Switzerland), and the University of Basel, Switzerland; unrestricted research grant from AstraZeneca; consultancy or advisory board fees or speaker honoraria from Amgen, Bayer, Bristol Myers Squibb, and Claret Medical; and travel grants from AstraZeneca and Bayer. Dr Kastner is an employee of Roche Diagnostics. Dr Sticherling reports speaker honoraria from Biosense Webster, Boston Scientific, and Medtronic; research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic; and serving as proctor for Medtronic (Cryoballoon). Dr Conen reports consultant/speaker fees from Servier Canada outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2020 Heart Rhythm Society",

year = "2021",

month = apr,

doi = "10.1016/j.hrthm.2020.11.028",

language = "English",

volume = "18",

pages = "512--519",

journal = "Heart Rhythm",

issn = "1547-5271",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation

AU - BEAT-AF and Swiss-AF investigators

AU - Blum, Steffen

AU - Aeschbacher, Stefanie

AU - Meyre, Pascal

AU - Kühne, Michael

AU - Rodondi, Nicolas

AU - Beer, Jürg H

AU - Ammann, Peter

AU - Moschovitis, Giorgio

AU - Bonati, Leo H

AU - Blum, Manuel R

AU - Kastner, Peter

AU - Baguley, Fiona

AU - Sticherling, Christian

AU - Osswald, Stefan

AU - Conen, David

AU - Conte, Giulio

N1 - Funding Information: Funding sources: BEAT-AF was supported by the Swiss National Science Foundation (PP00P3_159322), Swiss Heart Foundation, University of Basel, Roche Diagnostics, Boehringer-Ingelheim, Sanofi-Aventis, Merck Sharp & Dohme, Bayer, Daiichi-Sankyo, Pfizer/Bristol Myers Squibb, and the Foundation for Cardiovascular Research Basel. Swiss-AF was supported by grants from the Swiss National Science Foundation (33CS30_1148474 and 33CS30_177520), Foundation for Cardiovascular Research Basel, University of Basel, and Roche Diagnostics. Plasma levels of NT-proBNP and IGFBP-7 were measured free of charge by Roche Diagnostics. Dr Blum is supported by the Mach-Gaensslen Foundation outside the submitted work. Dr Conen holds a McMaster University Department of Medicine Mid-Career Research Award. Disclosures: Dr K\u00FChne reports fees from Speakers Bureau for Boston Scientific, St. Jude Medical, and Biotronik; lecture/consulting fees from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis, Medtronic, and Pfizer-BMS; unrestricted grants from Bayer and Pfizer-Bristol Myers Squibb; and serving as a proctor for Medtronic (Cryoballoon). Dr Rodondi reports a grant from the Swiss Heart Foundation. Dr Beer reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and Bayer; lecture fees from Sanofi Aventis and Amgen; and support to the institution outside the submitted work. Dr Bonati reports grants from the Swiss National Science Foundation, the Swiss Heart Foundation (Bern, Switzerland), and the University of Basel, Switzerland; unrestricted research grant from AstraZeneca; consultancy or advisory board fees or speaker honoraria from Amgen, Bayer, Bristol Myers Squibb, and Claret Medical; and travel grants from AstraZeneca and Bayer. Dr Kastner is an employee of Roche Diagnostics. Dr Sticherling reports speaker honoraria from Biosense Webster, Boston Scientific, and Medtronic; research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic; and serving as proctor for Medtronic (Cryoballoon). Dr Conen reports consultant/speaker fees from Servier Canada outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2020 Heart Rhythm Society

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: The occurrence of congestive heart failure (CHF) hospitalization among patients with atrial fibrillation (AF) is a poor prognostic marker.OBJECTIVE: The purpose of this study was to assess whether insulin-like growth factor-binding protein 7 (IGFBP-7), a marker of myocardial damage, identifies AF patients at high risk for this complication.METHODS: We analyzed 2 prospective multicenter observational cohort studies that included 3691 AF patients. Levels of IGFBP-7 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured from frozen plasma samples at baseline. The primary endpoint was hospitalization for CHF. Multivariable adjusted Cox regression analyses were constructed.RESULTS: Mean patient age was 69 ± 12 years, 1028 (28%) were female, and 879 (24%) had a history of CHF. The incidence per 1000 patient-years across increasing IGFBP-7 quartiles was 7, 10, 32, and 85. The corresponding multivariable adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.0, 1.05 (0.63-1.77), 2.38 (1.50-3.79), and 4.37 (2.72-7.04) (P for trend <.001). In a subgroup of 2812 patients without pre-existing CHF at baseline, the corresponding aHRs were 1.0, 0.90 (0.47-1.72), 1.69 (0.94-3.04), and 3.48 (1.94-6.24) (P for trend <.001). Patients with IGFBP-7 and NT-proBNP levels above the biomarker-specific median had a higher risk of incident CHF hospitalization (aHR 5.20; 3.35-8.09) compared to those with only 1 elevated marker (elevated IGFBP-7 aHR 2.17; 1.30-3.60); elevated NT-proBNP aHR 1.97; 1.17-3.33); or no elevated marker (reference).CONCLUSION: Higher plasma levels of IGFBP-7 were strongly and independently associated with CHF hospitalization in AF patients. The prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.

AB - BACKGROUND: The occurrence of congestive heart failure (CHF) hospitalization among patients with atrial fibrillation (AF) is a poor prognostic marker.OBJECTIVE: The purpose of this study was to assess whether insulin-like growth factor-binding protein 7 (IGFBP-7), a marker of myocardial damage, identifies AF patients at high risk for this complication.METHODS: We analyzed 2 prospective multicenter observational cohort studies that included 3691 AF patients. Levels of IGFBP-7 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured from frozen plasma samples at baseline. The primary endpoint was hospitalization for CHF. Multivariable adjusted Cox regression analyses were constructed.RESULTS: Mean patient age was 69 ± 12 years, 1028 (28%) were female, and 879 (24%) had a history of CHF. The incidence per 1000 patient-years across increasing IGFBP-7 quartiles was 7, 10, 32, and 85. The corresponding multivariable adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.0, 1.05 (0.63-1.77), 2.38 (1.50-3.79), and 4.37 (2.72-7.04) (P for trend <.001). In a subgroup of 2812 patients without pre-existing CHF at baseline, the corresponding aHRs were 1.0, 0.90 (0.47-1.72), 1.69 (0.94-3.04), and 3.48 (1.94-6.24) (P for trend <.001). Patients with IGFBP-7 and NT-proBNP levels above the biomarker-specific median had a higher risk of incident CHF hospitalization (aHR 5.20; 3.35-8.09) compared to those with only 1 elevated marker (elevated IGFBP-7 aHR 2.17; 1.30-3.60); elevated NT-proBNP aHR 1.97; 1.17-3.33); or no elevated marker (reference).CONCLUSION: Higher plasma levels of IGFBP-7 were strongly and independently associated with CHF hospitalization in AF patients. The prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.

KW - Aged

KW - Atrial Fibrillation/blood

KW - Biomarkers/blood

KW - Disease Progression

KW - Female

KW - Follow-Up Studies

KW - Heart Failure/blood

KW - Hospitalization/statistics & numerical data

KW - Humans

KW - Insulin-Like Growth Factor Binding Proteins/blood

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Retrospective Studies

UR - http://www.scopus.com/inward/record.url?scp=85100373002&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2020.11.028

DO - 10.1016/j.hrthm.2020.11.028

M3 - Article

C2 - 33278630

SN - 1547-5271

VL - 18

SP - 512

EP - 519

JO - Heart Rhythm

JF - Heart Rhythm

IS - 4

ER -

Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this